Breast Cancer Clinical Trials

Showing 561-580 of 5,597 trials

A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain

NCT05892068

The purpose of this study to see how the brain absorbs, distributes, and gets rid of tucatinib in people who have HER2+ cancers (breast cancer, NSCLC, CRC, or GEC) that have spread to the brain, and to learn more about how cancer cells develop resistance to treatment. The researchers will do research tests to look for genetic differences between HER2+ breast cancer that has spread to the brain and progressed during treatment with tucatinib and cancers that are being treated with tucatinib for the first time.

Metastatic Breast Cancer

Memorial Sloan Kettering Cancer Center9 participantsStarted May 2023

Basking Ridge, New Jersey, United States • Middletown, New Jersey, United States • Montvale, New Jersey, United States +4 more locations

RECRUITINGPhase 1

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

NCT06778863

Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A\*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

Advanced Solid TumorUnresectable Solid TumorMetastatic Solid Tumor+8 more

Clasp Therapeutics, Inc.90 participantsStarted Feb 2025

Scottsdale, Arizona, United States • Tucson, Arizona, United States • Los Angeles, California, United States +18 more locations

A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

Related Searches

Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer

Anatomical Landmarks for Chest Wall Perforators Used for Partial Breast Reconstruction

Surveillance MRI Registry for Patients Who Had Breast Cancer With Dense Breast Tissue

Pain and Functional Recovery After Mastectomy and IBR by Implant: Prepectoral Versus Subpectoral Technique

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

MammoScreen Breast Cancer Risk Assessment and Decision Aid for Breast Cancer Screening and Referrals

Integrative Approaches for Cancer Survivorship (IACS3)

Mobile Health App to Promote Participation of Black Women in Breast Cancer Clinical Trials

Cardiotoxicity Assessment and Reduction Through Exercise in BREAST Cancer

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Immunotherapy-related CRP Kinetics in Early and Metastatic Triple-negative Breast Cancer

An Optimized Ultrasound Twinkling Marker for the Imaging of Lymph Nodes in Patients With Clinically Node-Positive Breast Cancer, The UTMOST2 Trial

Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade

A Non-interventional Prospective Study of Early HER2-negative High-risk Breast Cancer and BRCA1/2 Mutations Prevalence in RussiA

Efficacy and Safety of Dexmedetomidine Added to Modified Pectoral's Block

Tirzepatide Weight Loss for MRD+ Early Breast Cancer